Chylomicrons in disease: A renaissance in lipidology. International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008

Atherosclerosis Supplements

Volumn 9, Issue 2, 2008, Pages 1-2

  Stalenhoef, Anton F H ^a   Watts, Gerald F ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN B48; BIOLOGICAL MARKER; CHYLOMICRON; LIPOPROTEIN; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; ARTERY DISEASE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; CHEMOTAXIS; CHOLESTEROL SYNTHESIS; DIABETES MELLITUS; DRUG TARGETING; EDITORIAL; ENDOTHELIUM CELL; GENETIC ASSOCIATION; INFLAMMATION; INSULIN RESISTANCE; INTESTINE CELL; LIFESTYLE; LIPOPROTEIN METABOLISM; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ALBERTA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHYLOMICRONS; CONGRESSES AS TOPIC; HUMANS;

EID: 50449089926     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2008.05.001     Document Type: Editorial

References (18)

1. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 60 3 (1979) 473-485
2. Nordestgaard B.G., Benn M., Schnohr P., and Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298 3 (2007) 299-308
3. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., and Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298 3 (2007) 309-316
4. Lairon D. Macronutrient intake and modulation on chylomicron production and clearance. Atherosclerosis suppl. (2008)
5. Cianflone K., Paglialunga S., and Roy C. Intestinally-derived lipids: metabolic regulation and consequences- an overview. Atherosclerosis suppl. (2008)
6. Feingold K.R., Wiley M.H., MacRay G., et al. The effect of diabetes mellitus on sterol synthesis in the intact rat. Diabetes 31 (1982) 388-395
7. Young N.L., Lopez D.R., and McNamara D.J. Contributions of absorbed dietary cholesterol and cholesterol synthesized in small intestine to hypercholesterolemia in diabetic rats. Diabetes 37 (1988) 1151-1156
8. Hsieh J., Hayashi A., Webb J., and Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity. Atherosclerosis suppl. (2008)
9. Vine D.F., Glimm D., and Proctor S.D. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic Syndrome. Atherosclerosis suppl. (2008)
10. Duez H., Pavlic M., and Lewis G. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atherosclerosis suppl. (2008)
11. Tomkin G.H. The intestine as a regulator of cholesterol homeostasis in diabetes. Atherosclerosis suppl. (2008)
12. Cohn J. Are we ready for a prospective study to investigate the role of chylomicrons in cardiovascular disease?. Atherosclerosis suppl. (2008)
13. Alipour A., Elte J.W., van Zaanen H.C., Rietveld A.P., and Castro Cabezas M. Novel aspects of postprandial lipemia in relation to atherosclerosis. Atherosclerosis suppl. (2008)
14. Botham K.M. Oxidation of chylomicron remnants and vascular dysfunction. Atherosclerosis suppl. (2008)
15. Perez-Martinez P., Perez-Jimenez F., Lopez-Miranda J., and Ordovas J.M. Influence of genetic factors in the modulation of postprandial lipemia. Atherosclerosis suppl. (2008)
16. Davis H., Basso F., Hoos L.M., Tetzloff G., Lally S.M., and Altmann S.W. Cholesterol Homeostasis by the Intestine: Lessons from Niemann-Pick C1 Like 1 (NPC1L1). Atherosclerosis suppl. (2008)
17. Takech R., Galloway S., Pallebage-Gamarallage M.M., and Mamo J.C.L. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. Atherosclerosis suppl. (2008)
18. Redgrave T.G. Chylomicrons in disease. Future challenges. Atherosclerosis suppl. (2008)